The pattern of pharmacological treatment of bipolar patients discharged from psychiatric units in Poland

Pharmacological Reports

Volumn 70, Issue 4, 2018, Pages 694-698

  Jaracz, Jan ^a   Rudnicka, Edyta Tetera ^b   Bierejszyk, Magdalena ^b   Witczyk, Kaja ^c   Raczyńska, Agnieszka ^c   Nowak, Wojciech ^c   Pisarczyk, Anna ^c   Woźniak, Krzysztof ^c   Czernaś, Wojciech ^b   Moniakowski, Adam ^d   Jaracz, Krystyna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Dr Witold Ginel General Hospital in Grajewo   (Poland)

^c Province Hospital for the Nervously and Mentally Ill   (Poland)

^d Psychiatric Wardl   (Poland)

Author keywords

Bipolar disorder; Mood stabilisers; Polypharmacy; Second generation antipsychotics

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; VALPROIC ACID; ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; FEMALE; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL PATIENT; POLAND; POLYPHARMACY; PSYCHIATRIC DEPARTMENT; PSYCHOPHARMACOTHERAPY; CLINICAL PRACTICE; DRUG UTILIZATION; HOSPITAL DISCHARGE; MENTAL HOSPITAL; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG UTILIZATION; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; LITHIUM; MALE; MIDDLE AGED; PATIENT DISCHARGE; POLYPHARMACY; PRACTICE PATTERNS, PHYSICIANS'; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85048796252     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2018.02.004     Document Type: Article

References (38)

1. Baastrup, P.C., Schou, M., Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16 (1967), 162–172.
2. Lambert, P.A., Borselli, S., Marcou, G., Long-term thymoregulative action of depamide in manic-depressive psychoses [in French]. Ann Med Psychol 2 (1971), 442–447.
3. Okuma, T., Inanaga, K., Otsuki, S., Sarai, K., Takahashi, R., Hazama, H., et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berlin) 73 (1981), 95–96.
4. Goodwin, G.M., Malhi, G.S., What is a mood stabilizer. Psychol Med 37 (2007), 609–661.
5. Malhi, G.S., Chengappa, K.N., Gershon, S., Ghaemi, S.N., Atypical mood stabilizers: a new role for neuroleptics. Bipolar Disord 13 (2011), 583–586.
6. Goodwin, G.M., Haddad, P.M., Ferrier, I.N., Aronson, J.K., Barnes, T., Cipriani, A., et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30 (2016), 495–553.
7. Grof, P., Excellent lithium responders: people whose lives have been changed by lithium prophylaxis. Birch, N.J., Gallicchio, V.S., Becker, R.W., (eds.) Lithium: 50 years of psychopharmacology, new perspectives in biomedical and clinical research, 1999, Weidner Publishing Group, Cheshire (CT), 36–51.
8. Al Jurdi, R.K., Marangell, L.B., Petersen, N.J., Martinez, M., Gyulai, L., Sajatovic, M., Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a recovered status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry 16 (2008), 922–933.
9. Weinstock, L.M., Gaudiano, B.A., Epstein-Lubow, G., Tezanos, K., Celis-Dehoyos, C.E., Miller, I.W., Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res 216 (2014), 24–30.
10. Haeberle, A., Greil, W., Russmann, S., Grohmann, R., Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry, 21, 2012 12:153.
11. Degli Esposti, L., Sangiorgi, D., Mencacci, C., Spina, E., Pasina, C., Alacqua, M., et al. Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. BMC Psychiatry, 14, 2014, 282.
12. Hung, G.C., Yang, S.Y., Chen, Y., Lin, S.K., Psychotropic polypharmacy for the treatment of bipolar disorder in Taiwan. Psychiatr Serv 65 (2014), 125–128.
13. Fornaro, M., De Berardis, D., Koshy, A.S., Perna, G., Valchera, A., Vancampfort, D., et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat 12 (2016), 719–735.
14. Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Beaulieu, S., Alda, M., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15 (2013), 1–44.
15. Grunze, H., Kasper, S., Goodwin, G., Bowden, C., Möller, H.J., The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. WFSBP task force on treatment guidelines for bipolar disorders. World J Biol Psychiatry 5 (2004), 120–135.
16. National Institute for Health and Care Excellence: Bipolar disorder (update): the management of bipolar disorder in adults, children and adolescents in primary and secondary care. (Clinical Guideline 185.) 2014. www.nice.org.uk/guidance/CG185/InformationForPublic.
17. Fountoulakis, K.N., Grunze, H., Vieta, E., Young, A., Yatham, L., Blier, P., et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol 20:2 (2017), 180–195.
18. Rybakowski, J., Dudek, D., Jaracz, J., Affective disorders. Jarema, M., (eds.) Standards of pharmacological treatment of some mental disorders, 2015, Via Medica, Gdańsk.
19. Peselow, E.D., Naghdechi, L., Pizano, D., IsHak, W.W., Polypharmacy in maintenance of bipolar disorder. Clin Neuropharmacol 39 (2016), 132–134.
20. Frye, M.A., Ketter, T.A., Leverich, G.S., Huggins, T., Lantz, C., Denicoff, K.D., et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61 (2000), 9–15.
21. Hayes, J., Prah, P., Nazareth, I., King, M., Walters, K., Petersen, I., et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS One, 6(12), 2011, e28725.
22. Pillarella, J., Higashi, A., Alexander, G.C., Conti, R., Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998–2009. Psychiatr Serv 63 (2012), 83–86.
23. Chang, C.M., Wu, C.S., Huang, Y.W., Chau, Y.L., Tsai, H.J., Utilization of psychopharmacological treatment among patients with newly diagnosed bipolar disorder from 2001 to 2010. J Clin Psychopharmacol 36 (2016), 32–44.
24. Sachs, G.S., Grossman, F., Ghaemi, S.N., Okamoto, A., Bowden, C.L., Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159 (2002), 1146–1154.
25. Tohen, M., Chengappa, K.N., Suppes, T., Zarate, C.A. Jr., Calabrese, J.R., Bowden, C.L., et al. A efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59 (2002), 62–69.
26. Vieta, E., T'Joen, C., McQuade, R.D., Carson, W.H. Jr., Marcus, R.N., Sanchez, R., et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 165 (2008), 1316–1325.
27. Sachs, G., Chengappa, K.N., Suppes, T., Mullen, J.A., Brecher, M., Devine, N.A., et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Dis 6 (2004), 213–223.
28. Tohen, M., Vieta, E., Calabrese, J., Ketter, T.A., Sachs, G., Bowden efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60 (2003), 1079–1088.
29. van der Loos, M.L., Mulder, P.G., Hartong, E.G., Blom, M.B., Vergouwen, A.C., de Keyzer, H.J., et al. LamLit Study Group efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 70 (2009), 223–231.
30. Geddes, J.R., Goodwin, G.M., Rendell, J., Azorin, J.M., Cipriani, A., Ostacher, M.J., Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375 (2010), 385–395.
31. Hochman, E., Krivoy, A., Schaffer, A., Weizman, A., Valevski, A., Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: a cohort study. Bipolar Disord 18 (2016), 684–691.
32. Lindström, L., Lindström, E., Nilsson, M., Höistad, M., Maintenance therapy with second-generation antipsychotics for bipolar disorder—a systematic review and meta-analysis. J Affect Disord 213 (2017), 138–150.
33. Panayiotopoulos, C.P., Ferrie, C.D., Knott, C., Robinson, R.O., Interaction of lamotrigine with sodium valproate. Lancet, 341(8842), 1993, 445.
34. Haslemo, T., Olsen, K., Lunde, H., Molden, E., Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking. Ther Drug Monit 34 (2012), 512–517.
35. Kim, B., Kim, S.J., Son, J.I., Joo, Y.H., Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord 105 (2008), 45–52.
36. Sachs, G.S., Peters, A.T., Sylvia, L., Grunze, H., Polypharmacy and bipolar disorder: what's personality got to do with it. Int J Neuropsychopharmacol 17 (2014), 1053–1061.
37. McGirr, A., Vöhringer, P.A., Ghaemi, S.N., Lam, R.W., Yatham, L.N., Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 3 (2016), 1138–1146.
38. Kim, Y., Santos, R., Gage, F.H., Marchetto, M.C., Molecular mechanisms of bipolar disorder: progress made and future challenges. Front Cell Neurosci, 14(11), 2017, 30.